

FLORIDA | Board of Pharmacy

February 7-8, 2017

Championsgate, Florida



Mark Mikhael, PharmD
Chair, Board of Pharmacy

Jeenu Philip, BPharm
Vice Chair, Board of Pharmacy

C. Erica White
Executive Director, Board of Pharmacy

1 **Tuesday, February 7, 2017**

2
3 The meeting was called to order by Dr. Mikhael, Chair. Those present for all or part of the meeting included the following:

4
5 **General Board Business started: 8:00 a.m.**

6
7 **MEMBERS PRESENT:**

8 Mark Mikhael, PharmD, Chair
9 Jeenu Philip, BPharm, Vice- Chair
10 Michele Weizer, PharmD
11 Goar Alvarez, PharmD
12 Gavin Meshad
13 Jeffrey J. Mesaros, PharmD, JD
14 Debra Glass, BPharm
15 David Bisailon

7 **STAFF PRESENT:**

8 Erica White, Executive Director
9 Bianca Bell, Program Operations Administrator

12 **BOARD COUNSEL:**

13 David Flynn, Assistant Attorney General

16
17 *Please note the minutes reflect the actual order agenda items were discussed and may differ from the agenda outline. AUDIO from this meeting can*
18 *be found online: <http://floridaspharmacy.gov/>*

19
20 **Tab 1 started: 8:02 a.m.**

21
22 **TAB 1: REPORTS**

23
24 **SECTION A: Chair's Report- Mark Mikhael, PharmD, Chair**

- 25
26 1. Committees and Liaisons
27 2. Convention Meeting Attendance

28
29 Resetting of different committees and liaisons. Sterile Compounding committee is now the Compounding Committee, chaired by Dr.
30 Weizer. Rules Committee is chaired by Dr. Mesaros. Controlled Substances Mr. Meshad is chair. Budget and FSHP liaison is Dr.
31 Weizer, Ms. Glass is Healthiest Weight, and Tripartite is Dr. Alvarez. Dr. Alvarez is official FPA liaison. Discussed the NABP,
32 MALTAGON and District 3 meetings. Also discussed ACPE accreditation visits.

33
34 **SECTION B: Executive Director's Report- C. Erica White, Executive Director**

- 35
36 1. FLDOH Boards Anti-Trust Liability
37 2. Non-Resident Sterile Compounding License Renewal (update)
38 3. Pharmacy Renewals
39 4. NABP Annual Meeting- Board Dinner (May 21, 2017)
40 5. Travel to National/State meetings
41 6. NABP State Newsletter Program
42 7. Pharmacy Wall Plaques- discussion
43 8. Board of Pharmacy Staff Descriptions/Contacts
44 9. 2017 Board Meeting Schedule

45 Dr. Weizer supports the Newsletter. Motion to approve by Mr. Philip, second by Dr. Mesaros. Motion carried. Dr. Mikhael brought up
46 use of social media. There was a discussion regarding wall certificates. Motion by Dr. Mesaros to send the calligraphy certificate in a
tube seconded by Mr. Meshad. Motion carried.

40 **SECTION C: Attorney General's Report- David Flynn, Assistant Attorney General**

41
42 **1. Monthly Rules Report**

43
44 Adoption of four rules Licensure by Endorsement, Standards of the Practice of Compounding, Special sterile compounding permit,
45 and disciplinary guidelines updates. All four sterile compounding rules are in the works. Discussed Annual Regulatory Plan. Will
46 most likely find rules to update, enhance or repeal.

1
2 **SECTION D: Investigative Services Report- Robert Difiore, Pharmaceutical Program Manager**

3
4 **1. Investigative Services Report**

5
6 Discussion:

7 Pharmacy inspections: Started with 6304 Completed 4269; complete 68%

8 SSCP inspections: Started with 539 Completed 318; complete 59%

9 503B Out of State Outsourcers: Breakdown below; complete 81%

10 32 Registered

11 12 Provided Compliant FDA inspections

12 4 have not responded to repeated emails, letters, and phone calls

13 16 requested Inspections

14 13 Completed

15 3 outstanding (will be completed by 2/25/17)

16
17 **Tab 1 ended: 8:45 a.m.**

18 **Tab 2 started: 8:45 a.m.**

19
20 **TAB 2: GENERAL BUSINESS:**

21
22 **SECTION A: Ratification of Issued Licenses/Certificates & Staffing Ratios**

- 23
24 1. Pharmacist (Licensure)(Client 2201) – 54 Motion by Dr. Weizer, seconded by Dr. Alvarez.
25 2. Pharmacist (Exam Eligibility)(Client 2201) – 1,777 Motion by Mr. Philip, seconded by Mr. Bisailon
26 3. Pharmacist Interns (Client 2202) – 54 Motion by Dr. Alvarez, seconded by Mr. Philip
27 4. Registered Pharmacy Technicians (Client 2208) – 674 Motion by Mr. Philip, seconded by Mr. Bisailon
28 5. Consultant Pharmacist (Client 2203) – 18 Motion by Mr. Philp, seconded by Mr. Bisailon
29 6. Nuclear Pharmacist (Client 2204) – 0
30 7. Pharmacy/Facilities (Client 2205) – 18 Motion by Mr. Philip, seconded by Dr. Alvarez
31 8. Nonresident Sterile Compounding (Client 2210) – 3 Motion by Mr. Philip, Second by Mr. Bisailon
32 9. CE Providers – 9 Motion by Dr. Alvarez, Second by Mr. Bisailon
33 10. CE Courses – 19 Motion by Mr. Philip, Second by Dr. Weizer
34 11. CE Individual Request (Approved) – 0
35 12. CE Individual Request (Denied) – 0

36
37 Mr. Meshad moved to ratify all licenses, seconded by Ms. Glass. Motion carried.

38
39 **SECTION B: Review and approval of minutes from prior meetings**

40
41 **December 13-14, 2016 – Full Board Meeting Minutes**

42
43 Motion to accept the minutes was made by Mr. Philip and seconded by Mr. Meshad. Motion carried.

44
45 **December 13, 2016 Rules Committee Meeting Minutes**

46
47 Dr. Weizer noted the following correction(s) to the minutes: Page 1, Dr. Weizer is incorrectly listed as Chair instead of Dr. Mesaros.
48 Motion to accept the minutes as amended was made by Dr. Alvarez and seconded by Mr. Bisailon. Motion carried.

49
50 **SECTION C: Petition for Declaratory Statement**

51
52 **1. Value Health Consultants DBA Butterfield Drugs, License Type 2205, File#4759**

53
54 Mr. Flynn discussed the process of filing for a Declaratory Statement. Mr. Bayo provided further clarification of the event. Mr. Bayo requested to
55 have the rule opened for additional development. Dr. Mesaros made a motion to continue the petition for declaratory statement, seconded
56 by Mr. Meshad. Motion carried.

57
58 **Tab 2 ended: 9:20 a.m.**

1 **Tab 3 started: 9:20 a.m.**

2
3 **TAB 3: APPLICATIONS REQUIRING BOARD REVIEW**

4
5 **SECTION A: PHARMACIST APPLICATIONS**

6
7 **1. Emil Veltre, License Type 2201, File#47409**

8
9 Mr. Veltre addressed the Board with his case. The test itself was discussed. Mr. Philip made a motion to grant Mr. Veltre to take the MPJE
10 for licensure, seconded by Mr. Bisailon. Motion carried.

11
12 **SECTION B: REGISTERED PHARMACY TECHNICIAN APPLICATIONS**

13
14 **1. Lisa Sheehan, License Type 2208, File#75165**

15
16 Ms. Sheehan disclosed information of the event. Mr. Flynn asked for clarification of the California 2014 test and for explanation of the additional
17 findings at the time of the event. Ms. Sheehan requested a continuance. Dr. Mikhael made a motion to for her to participate in PRN within
18 her one-year application for licensure, seconded by Mr. Philip. Motion carried.

19
20 **SECTION C: COMMUNITY PHARMACY PERMIT**

21
22 **1. ~~Central Logistics Management, 2205 File # 23821~~**

23
24 On 1/31/2017 applicant sent an e-mail to Aaron Coker requesting withdrawal of the application.

25
26 **Tab 3 ended: 9:40 a.m.**

27
28 **TAB 4: OTHER BUSINESS**

29
30 **1. ~~Presentation from Austin White~~**

31
32 This presentation has been re-scheduled for the April 2017 board meeting in Tampa, FL.

33
34 **Short break prior to beginning of rules discussion**

35
36
37 **Board of Pharmacy General Rules Discussion**

38
39 The discussion was called to order by Dr. Mikhael, Chair. Those present for all or part of the discussion included the following:

40
41 **Rules Discussion started: 10:03 a.m.**

42
43 **Rule 64B16-27.830 Standards of Practice- Drug Therapy Management**

44
45 Mr. Bayo came forward to provide historical feedback regarding the rule and stated in 1999 a change was made to the definition of
46 Pharmacy. Mr. Dalen approached and stated that for the second year in a row, his group is proposing a legislative bill to address
47 collaboration and drug therapy. Mr. Dix came forward and referenced current rules that could help to tie in this rule and the proposed
48 amendments.

49 **Old Business/ New Business**

50
51 **A) Rules relating to automation**

52
53 Dr. Mesaros gave a brief recap of the December meeting discussion relating to automation rules. He reminded the audience that Mr.
54 Harris is currently in the process of gathering information so these rules can best encompass the practice of automated pharmacies on
55 a widespread spectrum. He provided some clarification on the language pertaining to these proposed rules and stated that board
56 counsel is in the works of cleaning the language up as well. He asks that the public continues to provide information to Mr. Harris and
57 Mr. Flynn for board consideration.

1
2 **B) Long term care rule revisions**
3

4 Dr. Mesaros gave a brief recap of the December meeting discussion relating to long term care rule revisions. He commended the
5 Board and audience members for their participation in the discussion and stated he felt they did an excellent job of viewing this from a
6 patient's perspective and not a practice perspective. Mr. Flynn and Mr. Harris will continue to collaborate on these rule revisions and
7 welcome feedback from the public.
8

9 **C) New Business**

10 Although not rule specific, the request was made for board members to reach out to the Executive Director to participate in a rule
11 revision workshop.
12

13 **Rules committee discussion ended at: 11:30 a.m.**
14 **Compounding Committee discussion started: 11:30 a.m.**
15
16

17 **Board of Pharmacy Compounding Rules Discussion**

18
19
20 **Rule 64B16- 27.797 The Standards of Practice for Compounding Sterile Products**

21 It was established that the revisions to this rule are going to make the current rule more organized and not change the principle of the
22 rule itself. Dr. Weizer states that newest published proposal is not in effect yet and therefore cannot be endorsed as a current standard.
23
24

25 **FDA Guidance Documents**

26
27 **A) Compounding and Repackaging of Radiopharmaceuticals by Outsourcing Facilities**
28

29 Dr. Weizer highlighted that this guidance document refers to both sterile and non-sterile radiopharmaceutical products. The document
30 discusses how repackaging is not covered in the current guidelines. There are 3 different approved "minor deviations" as to which can
31 prolong shelf-life for some of these products. The document details the differences between compounding and repackaging.
32

33 **B) Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies and Federal
34 Facilities**
35

36 The guideline states that prior to the patient receiving the product, there must be a receipt of a valid prescription as well as
37 documentation on the patient chart indicating receipt. The FDA also states that it's allowable to have a compounded product in
38 advance of the patient prescription if the beyond use date is not exceeded and the volume of the product does not exceed the normal
39 history of patient prescriptions.
40

41 **C) Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act**
42

43 Dr. Weizer stated this guidance document was included as an FYI and a reference document for review.
44

45 **Compounding committee discussion ended at: 11:53 a.m.**

46 Motion by Mr. Philip for full board meeting to adjourn seconded by Ms. Glass at 11:55 am.
47

48 **Wednesday, February 8, 2017**
49

50 The meeting was called to order by Dr. Mikhael, Chair. Those present for all or part of the meeting included the following:
51

52 **General Board Business started: 8:00 a.m.**
53

54 **MEMBERS PRESENT:**
55 Mark Mikhael, PharmD, Chair
56 Jeenu Philip, BPharm, Vice-Chair

Board of Pharmacy
February 7-8, 2017

STAFF PRESENT:
Erica White, Executive Director
Bianca Bell, Program Operations Administrator

Page 5 of 9

1 Michele Weizer, PharmD
2 Goar Alvarez, PharmD
3 Debra Glass, PharmD
4 Gavin Meshad
5 Jeffrey J. Mesaros, PharmD, JD
6 David Bisailon

BOARD COUNSEL:
David Flynn, Assistant Attorney General

PROSECUTORS:
Matthew Witters, Assistant General Counsel
Christopher Jurich, Assistant General Counsel

7
8
9 *Please note the minutes reflect the actual order agenda items were discussed and may differ from the agenda outline. AUDIO from this meeting can
10 be found online: <http://floridaspharmacy.gov/>*

11
12 **Tab 5 started: 8:02 a.m.**

13
14 **TAB 5: COMMITTEE REPORTS AND ACTIONS (FROM 2/7/17)**

15
16 **1. Rules Committee, Dr. Mesaros, Committee Chair**

17
18 Dr. Mesaros gave a brief overview of the discussions that occurred during the general rules portion of the board meeting on Tuesday February 7,
19 2017. Discussed having an updated portion of the automation rule available by the April meeting.

20
21 **2. Compounding Committee, Dr. Weizer, Committee Chair**

22
23 Dr. Weizer gave a brief overview of the discussions that occurred during the compounding rules portion of the board meeting on Tuesday February
24 7, 2017.

25
26 **Tab 5 ended at 8:08 a.m.**

27 **Tab 6 started at: 8:09 a.m.**

28
29 **6: DISCIPLINARY CASES**

30
31 **SECTION A: RECOMMENDED ORDER**

32
33 **RO-1 Devone Lemar Flucker, R.P.T., Case #2016-02809**

34 **Dr. Mikhael & Ms. Glass recused due to participation on the Probable Cause Panel.**

35
36 During initial presentation of the case, respondent and counsel were not present. Respondent appeared untimely after case was
37 presented. Motion to accept the Recommended Order made by Dr. Weizer, seconded by Mr. Bisailon. Motion to adopt the
38 conclusions of law set forth in the Administrative Complaint and find that this constitutes a violation of the Pharmacy Practice Act
39 made by Dr. Weizer, seconded by Mr. Bisailon. Motion for revocation by Mr. Meshad seconded by Mr. Bisailon. Motion carried.
40 Motion to bifurcate for cost by Dr. Weizer and seconded by Dr. Alvarez. Motion carried.

41
42 **SECTION B: SETTLEMENT AGREEMENTS (APPEARANCE REQUIRED)**

43
44 **SA-1 Julia S Thompkins, R.P.T., Case#2015-26017**

45 **Dr. Weizer recused due to participation on the Probable Cause Panel.**

46
47 Respondent was present and was represented by counsel Mr. Dix. Motion to accept the request for continuance to the April 2017
48 Board meeting made by Dr. Weizer, seconded by Mr. Bisailon. Motion carried.

49
50 **SA-2 Southwest Florida Infusion Care, Inc., Case#2015-30232**

51 **Mr. Philip recused due to participation on the Probable Cause Panel.**

52
53 Respondent Johnny Myer was present and was represented by counsel, Mr. Bayo. Motion to accept continuance request to April made
54 by Dr. Weizer, seconded by Ms. Glass. Motion carried.

55
56 **SA-3 Norma J. Harris, R.Ph, Case#2015-30222**

57 **Mr. Philip recused due to participation on the Probable Cause Panel.**

1 Respondent was present and was represented by counsel, Mr. Bayo. Motion to accept the Settlement Agreement made by Ms. Glass,
2 seconded by Mr. Bisaillon. Motion carried.
3

4 **SA-4 Vinodbhal N Patel, R.Ph, Case#2016-08625**
5 **Dr. Glass & Dr. Alvarez recused due to participation on the Probable Cause Panel.**
6

7 Respondent was present and was represented by counsel, Mr. Rose. Motion to accept the Settlement Agreement made by Dr. Weizer,
8 seconded by Mr. Bisaillon. Motion carried.
9

10 **SA-5 Paradigm Healthcare Solutions, Case#2016-18558**
11 **Dr. Weizer & Mr. Bisaillon recused due to participation on the Probable Cause Panel.**
12

13 Respondent was present and was not represented by counsel. Motion to accept the Settlement Agreement made by Dr. Mesaros,
14 seconded by Dr. Alvarez. Motion carried.
15

16 **SA-6 Joseph Thomas Brown, R.Ph, Case#2016-16781**
17 **Dr. Glass & Dr. Alvarez recused due to participation on the Probable Cause Panel.**
18

19 Respondent was present and was represented by counsel, Mr. Bayo. The settlement agreement was presented and then orally amended
20 as follows: 1 year restriction prohibiting respondent from serving as PDM shall be a minimum of 2 years. Motion to accept the
21 amended Settlement Agreement made by Dr. Mesaros, seconded by Mr. Philip. Motion carried.
22

23 **SA-7 Pacifico National, Inc DBA Amex Pharmacy, Case#2015-06647**
24 **Dr. Mikhael recused due to participation on the Probable Cause Panel.**
25

26 Respondent was present and was represented by counsel, Mr. Bayo. Motion to accept the Settlement Agreement made by Dr. Weizer,
27 seconded by Ms. Glass. Motion carried.
28

29 **SECTION C: DETERMINATION OF WAIVERS**

30

31 **DOW-1 Vallejo's Pharmacy, Case#2015-28639**
32 **Dr. Mikhael & Ms. Glass recused due to participation on the Probable Cause Panel**
33

34 Respondent was not present and was not represented by counsel. Mr. Jurich represented the Department and presented the case to the
35 Board. Motion by Dr. Alvarez and seconded by Mr. Bisaillon to find that respondent was properly served and waived the right to a
36 formal hearing. Motion carried. Motion by Dr. Alvarez and seconded by Mr. Bisaillon, to accept the investigative report into evidence
37 for the purposes of imposing a penalty. Motion carried. Motion by Dr. Alvarez and seconded by Mr. Bisaillon, to adopt the
38 conclusions of law set forth in the Administrative Complaint and find that this constitutes a violation of the Pharmacy Practice Act.
39 Motion Carried. Recommended Penalty: Revocation. Motion by Dr. Alvarez and seconded by Mr. Bisaillon. Motion carried.
40

41 **DOW-2 Kim Elizabeth Schade, R.Ph, Case#2016-12067**
42 **Dr. Mikhael & Dr. Weizer recused due to participation on the Probable Cause Panel**
43

44 Respondent was not present and was not represented by counsel. Mr. Witters represented the Department and presented the case to the
45 Board. Motion by Ms. Glass and seconded by Mr. Bisaillon to find that respondent was properly served and waived the right to a
46 formal hearing. Motion carried. Motion by Ms. Glass and seconded by Mr. Bisaillon, to accept the investigative report into evidence
47 for the purposes of imposing a penalty. Motion carried. Motion by Ms. Glass and seconded by Mr. Bisaillon, to adopt the conclusions
48 of law set forth in the Administrative Complaint and find that this constitutes a violation of the Pharmacy Practice Act. Motion
49 Carried. Recommended Penalty: Revocation. Motion by Ms. Glass and seconded by Mr. Bisaillon. Motion carried.
50

51 **DOW-3 Grisel M Iribarnegaray, R.P.T., Case#2015-24112**
52 **Dr. Weizer & Mr. Bisaillon recused due to participation on the Probable Cause Panel**
53

54 Respondent was not present and was not represented by counsel. Mr. Jurich represented the Department and presented the case to the
55 Board. Motion by Dr. Alvarez and seconded by Ms. Glass to find that respondent was properly served and waived the right to a formal
56 hearing. Motion carried. Motion by Dr. Alvarez and seconded by Ms. Glass, to accept the investigative report into evidence for the
57 purposes of imposing a penalty. Motion carried. Motion by Dr. Alvarez and seconded by Ms. Glass, to adopt the conclusions of law

1 set forth in the Administrative Complaint and find that this constitutes a violation of the Pharmacy Practice Act. Motion Carried.
2 Recommended Penalty: Revocation. Motion by Dr. Alvarez and seconded by Ms. Glass. Motion carried.
3

4 **SECTION D: VOLUNTARY RELINQUISHMENTS**

6 **VR-1 Yaima Villaescusa, R.P.T., Case#2016-18168**

7 **Ms. Glass & Dr. Alvarez recused due to participation on the Probable Cause Panel**

8
9 Motion by Mr. Philip and seconded by Dr. Mesaros to accept Voluntary Relinquishment. Motion carried.
10

11 **VR-2 M & P Pharmacy Inc., Case#2016-14300**

12 **Mr. Philip recused due to participation on the Probable Cause Panel**

13
14 Motion by Dr. Weizer and seconded by Dr. Mesaros to accept Voluntary Relinquishment. Motion carried.
15

16 **VR-3 Tutela Management Group LLC, Case#2016-19522**

17 **Dr. Weizer & Mr. Bisailon recused due to participation on the Probable Cause Panel**

18
19 Motion by Mr. Philip and seconded by Dr. Alvarez to accept Voluntary Relinquishment. Motion carried.
20

21 **VR-4 Hills Pharmacy LLC., Case#2016-22567**

22 **Dr. Weizer & Mr. Bisailon recused due to participation on the Probable Cause Panel**

23
24 Motion by Mr. Philip and seconded by Dr. Alvarez to accept Voluntary Relinquishment. Motion carried.
25

26 **VR-5 Loni F Lopresti, R.P.T., Case#2016-20627**

27 **PCP Waived, Ms. Glass recused herself as an employee of CVS**

28
29 Motion by Mr. Philip and seconded by Dr. Weizer to accept Voluntary Relinquishment. Motion carried.
30

31 **SECTION E: INFORMALS**

33 **I-1 Isaiah Benjamin Salowitz, R.P.T., Case#2015-29939**

34 **Dr. Weizer recused due to participation on the Probable Cause Panel**

35
36 Respondent was not present and was not represented by counsel. Mr. Witters represented the Department and presented the case to the
37 Board. Motion by Ms. Glass and seconded by Dr. Alvarez to find that respondent was properly served and has requested an informal
38 hearing. Motion carried. Motion by Ms. Glass and seconded by Mr. Bisailon, to accept the investigative report into evidence for the
39 purposes of imposing a penalty. Motion carried. Motion by Ms. Glass and seconded by Mr. Bisailon, to adopt the conclusions of law
40 set forth in the Administrative Complaint and find that this constitutes a violation of the Pharmacy Practice Act. Motion Carried.
41 Recommended Penalty: Revocation. Motion by Ms. Glass and seconded by Mr. Bisailon. Motion carried.
42

43 **I-2 Optimun RX Pharmacy LLC, Case#2016-12903**

44 **Dr. Weizer & Mr. Bisailon recused due to participation on the Probable Cause Panel**

45
46 Respondent was not present and was not represented by counsel. Mr. Witters represented the Department and presented the case to the
47 Board. Motion by Ms. Glass and seconded by Dr. Alvarez to find that respondent was properly served and has requested an informal
48 hearing. Motion carried. Motion by Ms. Glass and seconded by Dr. Alvarez, to accept the investigative report into evidence for the
49 purposes of imposing a penalty. Motion carried. Motion by Ms. Glass and seconded by Dr. Alvarez, to adopt the conclusions of law
50 set forth in the Administrative Complaint and find that this constitutes a violation of the Pharmacy Practice Act. Recommended
51 Penalty: Revocation. Motion by Ms. Glass and seconded by Dr. Alvarez. Motion carried.
52

53 **I-3 Valentine Chike Okonkwo, R.Ph, Case#2016-11429**

54 **Dr. Mesaros recused due to participation on the Probable Cause Panel**

55
56 Respondent was not present and was not represented by counsel. Mr. Jurich represented the Department and presented the case to the
57 Board. Motion by Ms. Glass and seconded by Mr. Bisailon, to find that respondent was properly served and has requested an informal
58 hearing. Motion carried. Motion by Ms. Glass and seconded by Mr. Bisailon, to accept the investigative report into evidence for the

1 purposes of imposing a penalty. Motion carried. Motion by Ms. Glass and seconded by Mr. Bisailon, to adopt the conclusions of law
2 set forth in the Administrative Complaint and find that this constitutes a violation of the Pharmacy Practice Act. Recommended
3 Penalty: Revocation. Motion by Ms. Glass and seconded by Mr. Bisailon. Motion carried.
4

5 SECTION F: PROSECUTION SERVICES REPORT

7 1. Matthew Witters, Assistant General Counsel

8
9 Mr. Witters stated that the inventory as of January 3, 2017 is 275 cases. Mr. Witters asked the board to consider allowing PSU a
10 continuance for prosecuting the cases that are 1 year or older. Ms. Glass made a motion to allow the continuance, seconded by Dr.
11 Weizer. Motion carried.
12

13 **Tab 6 ended at 10:40 a.m.**

14 **Tab 7 started at 10:40 a.m.**

16 TAB 7: LICENSURE ISSUES

18 SECTION A: PETITION FOR TERMINATION OF PROBATION

20 1. Custom Meds, Case#2013-18732, License#PH12847

21
22 Respondent Jessica Dileo was present and sworn in. Respondent was represented by counsel, Mr. Dix. Motion by Dr. Weizer and
23 seconded by Dr. Mikhael to accept termination of probation. Motion carried.
24

26 2. Pine Island Drugs, Case#2014-16249, License#PH13774

27 Respondent Richard Weiner was present and sworn in. Respondent was not represented by counsel. Motion by Dr. Weizer to allow
28 termination of probation contingent upon Board Chair receiving a satisfactory second inspection. Seconded by Mr. Bisailon. Motion
29 carried.
30

32 3. Jessica Dileo, Case#2014-09491, License#PS44900

33 Respondent was present and sworn in. Respondent was represented by counsel, Mr. Dix. Motion by Dr. Weizer and seconded by Ms.
34 Glass to accept termination of probation. Motion carried.
35

36 SECTION B: REQUEST FOR PAYMENT EXTENSION

38 1. Lucretia D. Pitts, Case#2012-13389, License#PS24121

39
40 Respondent was present and sworn in. Respondent was not represented by counsel. Mr. Philip brought to light that the CE's
41 completed by Ms. Pitts are not typically the courses required by the Board. Due to the fact that our compliance section accepted these
42 credits, the Board will like to put on the record that these courses will be accepted for Ms. Pitts. Motion by Dr. Mesaros and seconded
43 by Dr. Weizer to accept CE credits. Dr. Weizer made a motion to accept the request for payment extension. Seconded by Dr. Mesaros.
44 Motion carried.
45

46 SECTION C: PETITION TO CHANGE CLOSURE DATE

48 1. Nemour's Children's Hospital, Case#2013-18732, License#PH26355

49
50 Respondents were represented by counsel, Mr. Bayo (Nemours) and Mr. Dix (Publix). Motion by Dr. Weizer and seconded by Dr.
51 Mikhael to re-issue both permits with the corrected effective date. Motion carried.
52

53 **Tab 7 ended at 11:30 a.m.**

54
55 Motion to adjourn full board meeting by Dr. Weizer and seconded by Dr. Alvarez.
56

57 **Meeting adjourned at 11:55 a.m.**